Publication & Citation Trends
Most Cited Works
Publications
59 total
Calculated Objective Response Rate (ORR) of 97% from Post-Hoc Analysis of a Phase 2 Multicenter Study to Evaluate the Efficacy of VP-315, an Investigational therapy for Basal Cell Carcinoma (BCC) OA
Cited by 1
Semantic Scholar
529 Exploratory analysis of a phase 2 multicenter study evaluating local immune activation in the tumor microenvironment 12 weeks post VP-315, an investigational therapy for basal cell carcinoma (BCC)
Cited by 0
Semantic Scholar
Results of a Phase 2 Multicenter Study to Evaluate the Efficacy of VP-315, an Investigational Therapy for Basal Cell Carcinoma OA
Cited by 0
Semantic Scholar
EFFICACY OF XT-150, A NOVEL NON-VIRAL GENE THERAPY DELIVERING IL-10v, ON MODERATE TO SEVERE PAIN DUE TO KNEE OSTEOARTHRITIS: PATIENT SUBGROUP ANALYSIS
Cited by 5
Semantic Scholar
Results of a Phase 2 Multicenter Study Evaluating the Safety and Tolerability of VP-315, an Investigational Therapy for Basal Cell Carcinoma OA
Cited by 0
Semantic Scholar
Clinical and Histological Clearance of VP-315: Exploratory Results of an Investigational Non-surgical Immunotherapy in Subjects with Biopsy Proven Basal Cell Carcinoma OA
Cited by 0
Semantic Scholar
Results from Part 1 Safety Run-in Period of a 2-part, Phase 2, Multicenter, Open-label, Proof-of-Concept Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of VP-315 in Subjects with Basal Cell Carcinoma OA
Cited by 0
Semantic Scholar
Targeted interleukin-10 plasmid DNA therapy in the treatment of osteoarthritis: Toxicology and pain efficacy assessments
Cited by 63
OpenAlex
Research Topics
Adenosine and Purinergic Signaling
(32)
Cardiac Ischemia and Reperfusion
(11)
Mechanical Circulatory Support Devices
(7)
Pain Mechanisms and Treatments
(6)
Nonmelanoma Skin Cancer Studies
(6)
Frequent Co-Authors
Affiliations
Ironwood Pharmaceuticals (United States)
University of Virginia Health System
Virginia College
Capital Group (United States)
Xalud Therapeutics (United States)